The health insurance companies (whether HEK / hkk participate in the respective lot depends on the name of the respective lot) pursue the goal of having discount agreements with all suitable pharmaceutical companies in accordance with Section 130a (8) of the Social Code Book V on the active substances, combinations of active substances or dosage forms, strengths close. The contract is concluded as part of the open house process:

Individual negotiations on the content of the contract are not conducted, uniform conditions apply. The health insurance companies do not guarantee exclusivity to individual contractual partners. The contract period is generally a maximum of 24 months, starting on 01.12.2023 at the earliest (any deviating start times will result from the information on the corresponding lot). The contract ends on 30.11.2025 at the latest (any exceptions may arise from the information provided in the corresponding lot), regardless of the date of conclusion of the contract. It is possible to join this open house procedure at any time within the term of the contract. All further information can be found in the participation and contract documents.

The non-exclusive discount contracts concluded in the open house procedure of health insurance companies are generally used to bridge the period between patent expiration of active substances, combinations of active substances or dosage forms, active ingredients and the entry into force of exclusive discount contracts pursuant to § 130a (8) of the German Civil Code V. House procedures are possible at any time within the contract period. A contract is concluded with all pharmaceutical entrepreneurs who meet the requirements of the self-declaration for admission and reliability contained in the process documents and confirm this in text form in accordance with § 126b BGB. This publication does not concern the award of a public contract within the meaning of the Procurement Law Directive (2014/24/EC) or antitrust procurement law. In the interest of informing interested pharmaceutical entrepreneurs as broadly as possible, this notice will be made in the supplement to the Official Journal of the European Union. The process name “open procedure” used in the context of this publication text (section IV.1.1)) and the indication of award criteria (item II.2.5)) are due to the specifications of the announcement form and have no further meaning. This and the use of the medium “TED” does not involve any submission to public procurement regulations whose validity is not mandatory by law or procurement regulations.

The non-exclusive discount contracts concluded in the open house procedure of health insurance companies are generally used to bridge the period between patent expiration of active substances, combinations of active substances or dosage forms, active ingredients and the entry into force of exclusive discount contracts pursuant to § 130a (8) of the German Civil Code V. House procedures are possible at any time within the contract period. A contract is concluded with all pharmaceutical entrepreneurs who meet the requirements of the self-declaration for admission and reliability contained in the process documents and confirm this in text form in accordance with § 126b BGB. This publication does not concern the award of a public contract within the meaning of the Procurement Law Directive (2014/24/EC) or antitrust procurement law. In the interest of informing interested pharmaceutical entrepreneurs as broadly as possible, this notice will be made in the supplement to the Official Journal of the European Union. The process name “open procedure” used in the context of this publication text (section IV.1.1)) and the indication of award criteria (item II.2.5)) are due to the specifications of the announcement form and have no further meaning. This and the use of the medium “TED” does not involve any submission to public procurement regulations whose validity is not mandatory by law or procurement regulations.

The non-exclusive discount contracts concluded in the open house procedure of health insurance companies are generally used to bridge the period between patent expiration of active substances, combinations of active substances or dosage forms, active ingredients and the entry into force of exclusive discount contracts pursuant to § 130a (8) of the German Civil Code V. House procedures are possible at any time within the contract period. A contract is concluded with all pharmaceutical entrepreneurs who meet the requirements of the self-declaration for admission and reliability contained in the process documents and confirm this in text form in accordance with § 126b BGB. This publication does not concern the award of a public contract within the meaning of the Procurement Law Directive (2014/24/EC) or antitrust procurement law. In the interest of informing interested pharmaceutical entrepreneurs as broadly as possible, this notice will be made in the supplement to the Official Journal of the European Union. The process name “open procedure” used in the context of this publication text (section IV.1.1)) and the indication of award criteria (item II.2.5)) are due to the specifications of the announcement form and have no further meaning. This and the use of the medium “TED” does not involve any submission to public procurement regulations whose validity is not mandatory by law or procurement regulations.

The non-exclusive discount contracts concluded in the open house procedure of health insurance companies are generally used to bridge the period between patent expiration of active substances, combinations of active substances or dosage forms, active ingredients and the entry into force of exclusive discount contracts pursuant to § 130a (8) of the German Civil Code V. House procedures are possible at any time within the contract period. A contract is concluded with all pharmaceutical entrepreneurs who meet the requirements of the self-declaration for admission and reliability contained in the process documents and confirm this in text form in accordance with § 126b BGB. This publication does not concern the award of a public contract within the meaning of the Procurement Law Directive (2014/24/EC) or antitrust procurement law. In the interest of informing interested pharmaceutical entrepreneurs as broadly as possible, this notice will be made in the supplement to the Official Journal of the European Union. The process name “open procedure” used in the context of this publication text (section IV.1.1)) and the indication of award criteria (item II.2.5)) are due to the specifications of the announcement form and have no further meaning. This and the use of the medium “TED” does not involve any submission to public procurement regulations whose validity is not mandatory by law or procurement regulations.

The non-exclusive discount contracts concluded in the open house procedure of health insurance companies are generally used to bridge the period between patent expiration of active substances, combinations of active substances or dosage forms, active ingredients and the entry into force of exclusive discount contracts pursuant to § 130a (8) of the German Civil Code V. House procedures are possible at any time within the contract period. A contract is concluded with all pharmaceutical entrepreneurs who meet the requirements of the self-declaration for admission and reliability contained in the process documents and confirm this in text form in accordance with § 126b BGB. This publication does not concern the award of a public contract within the meaning of the Procurement Law Directive (2014/24/EC) or antitrust procurement law. In the interest of informing interested pharmaceutical entrepreneurs as broadly as possible, this notice will be made in the supplement to the Official Journal of the European Union. The process name “open procedure” used in the context of this publication text (section IV.1.1)) and the indication of award criteria (item II.2.5)) are due to the specifications of the announcement form and have no further meaning. This and the use of the medium “TED” does not involve any submission to public procurement regulations whose validity is not mandatory by law or procurement regulations.

The non-exclusive discount contracts concluded in the open house procedure of health insurance companies are generally used to bridge the period between patent expiration of active substances, combinations of active substances or dosage forms, active ingredients and the entry into force of exclusive discount contracts pursuant to § 130a (8) of the German Civil Code V. House procedures are possible at any time within the contract period. A contract is concluded with all pharmaceutical entrepreneurs who meet the requirements of the self-declaration for admission and reliability contained in the process documents and confirm this in text form in accordance with § 126b BGB. This publication does not concern the award of a public contract within the meaning of the Procurement Law Directive (2014/24/EC) or antitrust procurement law. In the interest of informing interested pharmaceutical entrepreneurs as broadly as possible, this notice will be made in the supplement to the Official Journal of the European Union. The process name “open procedure” used in the context of this publication text (section IV.1.1)) and the indication of award criteria (item II.2.5)) are due to the specifications of the announcement form and have no further meaning. This and the use of the medium “TED” does not involve any submission to public procurement regulations whose validity is not mandatory by law or procurement regulations.

The non-exclusive discount contracts concluded in the open house procedure of health insurance companies are generally used to bridge the period between patent expiration of active substances, combinations of active substances or dosage forms, active ingredients and the entry into force of exclusive discount contracts pursuant to § 130a (8) of the German Civil Code V. House procedures are possible at any time within the contract period. A contract is concluded with all pharmaceutical entrepreneurs who meet the requirements of the self-declaration for admission and reliability contained in the process documents and confirm this in text form in accordance with § 126b BGB. This publication does not concern the award of a public contract within the meaning of the Procurement Law Directive (2014/24/EC) or antitrust procurement law. In the interest of informing interested pharmaceutical entrepreneurs as broadly as possible, this notice will be made in the supplement to the Official Journal of the European Union. The process name “open procedure” used in the context of this publication text (section IV.1.1)) and the indication of award criteria (item II.2.5)) are due to the specifications of the announcement form and have no further meaning. This and the use of the medium “TED” does not involve any submission to public procurement regulations whose validity is not mandatory by law or procurement regulations.

The non-exclusive discount contracts concluded in the open house procedure of health insurance companies are generally used to bridge the period between patent expiration of active substances, combinations of active substances or dosage forms, active ingredients and the entry into force of exclusive discount contracts pursuant to § 130a (8) of the German Civil Code V. House procedures are possible at any time within the contract period. A contract is concluded with all pharmaceutical entrepreneurs who meet the requirements of the self-declaration for admission and reliability contained in the process documents and confirm this in text form in accordance with § 126b BGB. This publication does not concern the award of a public contract within the meaning of the Procurement Law Directive (2014/24/EC) or antitrust procurement law. In the interest of informing interested pharmaceutical entrepreneurs as broadly as possible, this notice will be made in the supplement to the Official Journal of the European Union. The process name “open procedure” used in the context of this publication text (section IV.1.1)) and the indication of award criteria (item II.2.5)) are due to the specifications of the announcement form and have no further meaning. This and the use of the medium “TED” does not involve any submission to public procurement regulations whose validity is not mandatory by law or procurement regulations.

The non-exclusive discount contracts concluded in the open house procedure of health insurance companies are generally used to bridge the period between patent expiration of active substances, combinations of active substances or dosage forms, active ingredients and the entry into force of exclusive discount contracts pursuant to § 130a (8) of the German Civil Code V. House procedures are possible at any time within the contract period. A contract is concluded with all pharmaceutical entrepreneurs who meet the requirements of the self-declaration for admission and reliability contained in the process documents and confirm this in text form in accordance with § 126b BGB. This publication does not concern the award of a public contract within the meaning of the Procurement Law Directive (2014/24/EC) or antitrust procurement law. In the interest of informing interested pharmaceutical entrepreneurs as broadly as possible, this notice will be made in the supplement to the Official Journal of the European Union. The process name “open procedure” used in the context of this publication text (section IV.1.1)) and the indication of award criteria (item II.2.5)) are due to the specifications of the announcement form and have no further meaning. This and the use of the medium “TED” does not involve any submission to public procurement regulations whose validity is not mandatory by law or procurement regulations.

The non-exclusive discount contracts concluded in the open house procedure of health insurance companies are generally used to bridge the period between patent expiration of active substances, combinations of active substances or dosage forms, active ingredients and the entry into force of exclusive discount contracts pursuant to § 130a (8) of the German Civil Code V. House procedures are possible at any time within the contract period. A contract is concluded with all pharmaceutical entrepreneurs who meet the requirements of the self-declaration for admission and reliability contained in the process documents and confirm this in text form in accordance with § 126b BGB. This publication does not concern the award of a public contract within the meaning of the Procurement Law Directive (2014/24/EC) or antitrust procurement law. In the interest of informing interested pharmaceutical entrepreneurs as broadly as possible, this notice will be made in the supplement to the Official Journal of the European Union. The process name “open procedure” used in the context of this publication text (section IV.1.1)) and the indication of award criteria (item II.2.5)) are due to the specifications of the announcement form and have no further meaning. This and the use of the medium “TED” does not involve any submission to public procurement regulations whose validity is not mandatory by law or procurement regulations.

The non-exclusive discount contracts concluded in the open house procedure of health insurance companies are generally used to bridge the period between patent expiration of active substances, combinations of active substances or dosage forms, active ingredients and the entry into force of exclusive discount contracts pursuant to § 130a (8) of the German Civil Code V. House procedures are possible at any time within the contract period. A contract is concluded with all pharmaceutical entrepreneurs who meet the requirements of the self-declaration for admission and reliability contained in the process documents and confirm this in text form in accordance with § 126b BGB. This publication does not concern the award of a public contract within the meaning of the Procurement Law Directive (2014/24/EC) or antitrust procurement law. In the interest of informing interested pharmaceutical entrepreneurs as broadly as possible, this notice will be made in the supplement to the Official Journal of the European Union. The process name “open procedure” used in the context of this publication text (section IV.1.1)) and the indication of award criteria (item II.2.5)) are due to the specifications of the announcement form and have no further meaning. This and the use of the medium “TED” does not involve any submission to public procurement regulations whose validity is not mandatory by law or procurement regulations.

The non-exclusive discount contracts concluded in the open house procedure of health insurance companies are generally used to bridge the period between patent expiration of active substances, combinations of active substances or dosage forms, active ingredients and the entry into force of exclusive discount contracts pursuant to § 130a (8) of the German Civil Code V. House procedures are possible at any time within the contract period. A contract is concluded with all pharmaceutical entrepreneurs who meet the requirements of the self-declaration for admission and reliability contained in the process documents and confirm this in text form in accordance with § 126b BGB. This publication does not concern the award of a public contract within the meaning of the Procurement Law Directive (2014/24/EC) or antitrust procurement law. In the interest of informing interested pharmaceutical entrepreneurs as broadly as possible, this notice will be made in the supplement to the Official Journal of the European Union. The process name “open procedure” used in the context of this publication text (section IV.1.1)) and the indication of award criteria (item II.2.5)) are due to the specifications of the announcement form and have no further meaning. This and the use of the medium “TED” does not involve any submission to public procurement regulations whose validity is not mandatory by law or procurement regulations.

The non-exclusive discount contracts concluded in the open house procedure of health insurance companies are generally used to bridge the period between patent expiration of active substances, combinations of active substances or dosage forms, active ingredients and the entry into force of exclusive discount contracts pursuant to § 130a (8) of the German Civil Code V. House procedures are possible at any time within the contract period. A contract is concluded with all pharmaceutical entrepreneurs who meet the requirements of the self-declaration for admission and reliability contained in the process documents and confirm this in text form in accordance with § 126b BGB. This publication does not concern the award of a public contract within the meaning of the Procurement Law Directive (2014/24/EC) or antitrust procurement law. In the interest of informing interested pharmaceutical entrepreneurs as broadly as possible, this notice will be made in the supplement to the Official Journal of the European Union. The process name “open procedure” used in the context of this publication text (section IV.1.1)) and the indication of award criteria (item II.2.5)) are due to the specifications of the announcement form and have no further meaning. This and the use of the medium “TED” does not involve any submission to public procurement regulations whose validity is not mandatory by law or procurement regulations.